Mar 25 |
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
|
Mar 22 |
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall
|
Mar 22 |
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
|
Mar 14 |
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
|
Mar 14 |
Q4 2023 Sangamo Therapeutics Inc Earnings Call
|
Mar 13 |
Sangamo Therapeutics GAAP EPS of -$0.34 misses by $0.08, revenue of $2.04M misses by $6.07M
|
Mar 13 |
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
Mar 13 |
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
|
Mar 13 |
Earnings Scheduled For March 13, 2024
|
Mar 12 |
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
|